EA201990951A1 - Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение - Google Patents
Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применениеInfo
- Publication number
- EA201990951A1 EA201990951A1 EA201990951A EA201990951A EA201990951A1 EA 201990951 A1 EA201990951 A1 EA 201990951A1 EA 201990951 A EA201990951 A EA 201990951A EA 201990951 A EA201990951 A EA 201990951A EA 201990951 A1 EA201990951 A1 EA 201990951A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor
- vap
- application
- disorders
- ssao
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
Изобретение относится к фармацевтической комбинации в соответствии с изобретением, содержащей SSAO/VAP-1 ингибитор в соответствии с формулой (I)где R-Rи X имеют значения, как определено в настоящей заявке, и SGLT2-ингибитор. Дополнительно настоящее изобретение относится к способам предотвращения, замедления прогрессирования, задержки или лечения фиброзных нарушений, метаболических нарушений, воспалительных нарушений, глазных болезней, нейровоспалительных нарушений или злокачественного новообразования у пациента, который в этом нуждается, характеризующимся тем, что фармацевтическую комбинацию в соответствии с изобретением вводят пациенту.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16194572 | 2016-10-19 | ||
PCT/EP2017/076300 WO2018073154A1 (en) | 2016-10-19 | 2017-10-16 | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201990951A1 true EA201990951A1 (ru) | 2019-11-29 |
Family
ID=57178303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990951A EA201990951A1 (ru) | 2016-10-19 | 2017-10-16 | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210212968A1 (ru) |
EP (1) | EP3528800A1 (ru) |
JP (1) | JP2019531320A (ru) |
KR (1) | KR20190070956A (ru) |
CN (1) | CN109843279A (ru) |
AU (1) | AU2017344882A1 (ru) |
BR (1) | BR112019005930A2 (ru) |
CA (1) | CA3041169A1 (ru) |
CL (1) | CL2019000935A1 (ru) |
EA (1) | EA201990951A1 (ru) |
IL (1) | IL265989A (ru) |
MX (1) | MX2019004549A (ru) |
PH (1) | PH12019500845A1 (ru) |
WO (1) | WO2018073154A1 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190110736A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
KR20190110740A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
BR112021005920A2 (pt) * | 2018-09-28 | 2021-06-29 | Acucela Inc. | inibidores de vap-1 |
MX2021003559A (es) * | 2018-09-28 | 2021-08-24 | Acucela Inc | Inhibidores de vap-1. |
JP7414230B2 (ja) * | 2018-11-09 | 2024-01-16 | 国立大学法人 琉球大学 | 抗血液悪性腫瘍薬 |
TW202039486A (zh) * | 2018-12-14 | 2020-11-01 | 南韓商柳韓洋行股份有限公司 | 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物 |
EP3894398A4 (en) * | 2018-12-14 | 2022-09-14 | Yuhan Corporation | 3,3-DIFLUORALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF |
BR112022007974A2 (pt) | 2019-10-29 | 2022-07-12 | Eccogene Shanghai Co Ltd | Inibidores de ssao e uso dos mesmos |
WO2021195435A1 (en) * | 2020-03-25 | 2021-09-30 | Terns, Inc. | Treatment of respiratory disorders |
IL298145A (en) * | 2020-05-13 | 2023-01-01 | Terns Pharmaceuticals Inc | Combined treatment of liver disorders |
CN113893256A (zh) * | 2020-07-06 | 2022-01-07 | 诺未科技(北京)有限公司 | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 |
US11820754B2 (en) | 2020-08-25 | 2023-11-21 | Eli Lilly And Company | Polymorphs of an SSAO inhibitor |
WO2022183289A1 (en) * | 2021-03-04 | 2022-09-09 | The Governors Of The University Of Alberta | The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease |
TW202333726A (zh) * | 2021-11-11 | 2023-09-01 | 美商拓臻製藥公司 | 以ssao抑制劑治療肝病 |
US20230241071A1 (en) * | 2021-11-11 | 2023-08-03 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ517439A (en) | 1999-08-31 | 2003-03-28 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
WO2002044192A1 (fr) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions |
NZ526715A (en) | 2000-12-28 | 2005-02-25 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
PL210710B1 (pl) | 2002-03-22 | 2012-02-29 | Kissei Pharmaceutical | Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
WO2004080990A1 (ja) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-グリコシド誘導体又はその塩 |
PT2896397T (pt) | 2003-08-01 | 2017-11-23 | Mitsubishi Tanabe Pharma Corp | Novos compostos que possuem actividade inibidora dirigida contra transportadores de glucose dependentes do sódio |
EP2295422A3 (de) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
UA91546C2 (ru) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(b-D-ГЛЮКОПИРАНОЗ-1- ИЛ)-2-[4-((S)- ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ ПРИ ПРИГОТАВЛЕНИИ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
EP2019679B1 (en) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
WO2008109591A1 (en) | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
ATE530558T1 (de) | 2007-07-26 | 2011-11-15 | Lexicon Pharmaceuticals Inc | Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern |
BRPI0816258B8 (pt) | 2007-09-10 | 2022-12-27 | Mitsubishi Tanabe Pharma Corp | processo para a preparação de compostos úteis como inibidores de sglt |
CN101917845A (zh) | 2007-11-21 | 2010-12-15 | 法马克西斯制药公司 | Ssao/vap-1的卤代烯丙胺抑制剂及其用途 |
TW201011043A (en) | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
BRPI0918841B8 (pt) | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
EP2395968B1 (en) | 2009-02-13 | 2024-01-17 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient |
NZ623838A (en) | 2009-04-16 | 2015-09-25 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions for the treatment of diabetes mellitus |
WO2011039107A1 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
IN2012DN02751A (ru) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
PT2844637T (pt) | 2012-05-02 | 2018-04-17 | Boehringer Ingelheim Int | Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações |
-
2017
- 2017-10-16 CN CN201780063937.5A patent/CN109843279A/zh active Pending
- 2017-10-16 WO PCT/EP2017/076300 patent/WO2018073154A1/en unknown
- 2017-10-16 AU AU2017344882A patent/AU2017344882A1/en not_active Abandoned
- 2017-10-16 MX MX2019004549A patent/MX2019004549A/es unknown
- 2017-10-16 CA CA3041169A patent/CA3041169A1/en not_active Abandoned
- 2017-10-16 BR BR112019005930A patent/BR112019005930A2/pt not_active IP Right Cessation
- 2017-10-16 EP EP17804068.9A patent/EP3528800A1/en not_active Withdrawn
- 2017-10-16 KR KR1020197014347A patent/KR20190070956A/ko not_active Application Discontinuation
- 2017-10-16 JP JP2019520691A patent/JP2019531320A/ja active Pending
- 2017-10-16 EA EA201990951A patent/EA201990951A1/ru unknown
- 2017-10-16 US US16/341,460 patent/US20210212968A1/en not_active Abandoned
-
2019
- 2019-04-08 CL CL2019000935A patent/CL2019000935A1/es unknown
- 2019-04-11 IL IL265989A patent/IL265989A/en unknown
- 2019-04-17 PH PH12019500845A patent/PH12019500845A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019531320A (ja) | 2019-10-31 |
US20210212968A1 (en) | 2021-07-15 |
EP3528800A1 (en) | 2019-08-28 |
IL265989A (en) | 2019-06-30 |
MX2019004549A (es) | 2019-06-12 |
CA3041169A1 (en) | 2018-04-26 |
WO2018073154A1 (en) | 2018-04-26 |
BR112019005930A2 (pt) | 2019-06-11 |
PH12019500845A1 (en) | 2019-12-02 |
CL2019000935A1 (es) | 2019-08-09 |
CN109843279A (zh) | 2019-06-04 |
KR20190070956A (ko) | 2019-06-21 |
AU2017344882A1 (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
EA201790660A1 (ru) | Ингибитор киназ | |
EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
PH12016502352A1 (en) | Pharmaceutical composition | |
PH12016502353A1 (en) | Pharmaceutical composition | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
EA201892297A1 (ru) | Способы лечения холестатических и фибротических заболеваний | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
EP4279925A3 (en) | Dulaglutide for the treatment of chronic kidney disease | |
EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
EA201800565A1 (ru) | Композиция для лечения заболеваний уха, содержащая (+)-азасетрон | |
EA201992386A1 (ru) | Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. |